Project Grant K01CA313805
Award Date 5/7/26
Completion Date 4/30/29
Dollars Obligated $132K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
- Federal Project Grant Award Summary The University of Texas Southwestern Medical Center received a $166,000 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective May 1, 2026 through April 30, 2028. This award funds research aimed at identifying and targeting cell death pathways to prevent resistance to KRAS inhibitors in pancreatic ductal adenocarcinoma (PDAC). The project focuses on developing and validating two novel...
- Federal Grant Award Summary The University of Texas Southwestern Medical Center received a $639,514 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) effective June 1, 2026, through May 31, 2031. This five-year research initiative funds mechanistic characterization studies of benzothiazepinone compounds, specifically MM17, which inhibit NVL (a critical AAA+ adenosine triphosphatase enzyme involved in ribosomal subunit...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Regents of the University of California, San Francisco a $675,009 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2026, with a completion date of July 31, 2031. This research initiative, led by a cross-disciplinary collaboration between experts in RAS (Rat sarcoma) protein drugging and cancer signaling, focuses on developing novel covalent inhibitors targeting RAS Q61 mutations...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Pittsburgh a $657,776 Project Grant under the Cancer Treatment Research program (CFDA 93.395) beginning August 1, 2025, and extending through May 31, 2030. This award supports the development of highly tumor-selective pan RAS inactivators to address oncogenic RAS-driven cancers, which account for approximately 46% of all human malignancies. The project addresses a significant clinical challenge: while...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $402,011 Project Grant to The University of Texas Southwestern Medical Center under the Cancer Biology Research program (CFDA 93.396) effective May 1, 2026, through April 30, 2031. This five-year research initiative investigates the molecular mechanisms by which the KEAP1-NRF2 redox-sensing pathway regulates CD8 T cell adaptation to chronic antigen receptor signaling in cancer and chronic infection contexts. The research...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Ohio State University $463,692 under the Cancer Biology Research program (CFDA 93.396) to conduct fundamental research on the structural and dynamic characterization of human K-RAS protein and its interactions with binding partners and small-molecule ligands. The project, which commenced June 1, 2026, and concludes May 31, 2031, employs state-of-the-art experimental and computational methods to investigate K-RAS in...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The University of Texas Southwestern Medical Center a Project Grant of $426,828 under the Cancer Treatment Research program (CFDA 93.395) on May 4, 2026, with a completion date of April 30, 2028. This research grant supports the validation and translation of findings regarding JUMONJI KDM5 histone demethylase enzymes and their role in mediating resistance to CDK4/6 inhibitors in estrogen receptor-positive (ER+) breast...
- Federal Grant Award Summary New York University School of Medicine received a $435,827 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective June 4, 2025, with completion targeted for May 31, 2027. The grant supports research entitled "Exploiting Synthetic Lethality to Enhance KRAS Inhibitor Therapy of Cancer," which investigates combination therapeutic strategies to overcome intrinsic and emergent resistance to...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $375,150 to The Regents of the University of California, San Francisco under the Cancer Treatment Research program (CFDA 93.395) to fund a five-year research initiative (September 1, 2025 – August 31, 2030). The research addresses innate resistance mechanisms to KRAS inhibitors in cancer treatment, focusing on the role of the RhoA-ROCK-Myosin IIA cytoskeletal axis in promoting drug-tolerant persister...
- Federal Grant Award Summary Duke University received a $411,152 Project Grant from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) awarded September 5, 2025, with completion targeted for August 31, 2027. The award supports research to identify and validate noncovalent protein interactions of mutant KRAS (MKRAS) inhibitors, specifically examining how four therapeutic compounds—sotorasib, divarasib, MRTX1133, and RMC-6236—interact with proteins beyond their intended...